Rispaxol may be available in the countries listed below.
Ingredient matches for Rispaxol
Risperidone is reported as an ingredient of Rispaxol in the following countries:
- Latvia
International Drug Name Search
Rispaxol may be available in the countries listed below.
Risperidone is reported as an ingredient of Rispaxol in the following countries:
International Drug Name Search
Ph. Eur.
A12AA01
0007758-87-4
Ca3(P-O4)2 + Ca-H-P-O4
Pharmaceutic aid
Antacid
Mineral supplement
Calcium phosphate (3:2) mixture with calcium phosphate (1:1)
International Drug Name Search
Glossary
BP | British Pharmacopoeia |
IS | Inofficial Synonym |
PH | Pharmacopoeia Name |
Ph. Eur. | European Pharmacopoeia |
Ph. Int. | Pharmacopoea Internationalis |
LisiLich comp may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of LisiLich comp in the following countries:
Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of LisiLich comp in the following countries:
International Drug Name Search
In the US, Ortho Evra (ethinyl estradiol/norelgestromin systemic) is a member of the drug class contraceptives and is used to treat Birth Control.
US matches:
Ethinylestradiol is reported as an ingredient of Ortho Evra in the following countries:
Norelgestromin is reported as an ingredient of Ortho Evra in the following countries:
International Drug Name Search
Perkapil may be available in the countries listed below.
Dipyrithione is reported as an ingredient of Perkapil in the following countries:
International Drug Name Search
Class: Opiate Partial Agonists
VA Class: CN101
Chemical Name: [5α,7α(5)] - 17 - (Cyclopropylmethyl) - α - (1,1 - dimethylethyl) - 4,5 - epoxy - 18,19 - dihydro - 3 - hydroxy - 6 - methoxy - α - methyl - 6,14 - ethinomorphinan - 7 - methanol hydrochloride
Molecular Formula: C29H41NO4•HCl
CAS Number: 53152-21-9
Brands: Buprenex, Suboxone, Subutex
REMS:
FDA approved a REMS for buprenorphine to ensure that the benefits of a drug outweigh the risks. The REMS may apply to one or more preparations of buprenorphine and consists of the following: medication guide, elements to assure safe use, and implementation system. See the FDA REMS page () or the ASHP REMS Resource Center ().
Analgesic; opiate partial agonist.1 2 3 4 6 7 10 11 202
Relief of moderate to severe pain1 2 3 4 124 183 185 such as that associated with acute and chronic medical disorders including cancer,31 65 71 99 134 143 trigeminal neuralgia,47 accidental trauma,73 ureteral calculi,98 and MI.4 71 150
Management of postoperative pain in patients who have undergone various types of surgery, including neurologic,138 cardiovascular (e.g., CABG, valve replacement),4 66 71 185 cesarean section,28 71 82 110 gynecologic,28 60 69 71 80 124 149 151 177 abdominal (e.g., cholecystectomy, bowel resection),28 32 44 54 64 69 71 73 76 103 145 151 184 185 urologic,28 124 185 general (e.g., head and neck, breast),53 60 151 and orthopedic (e.g., total hip replacement, spinal fusion).23 26 32 83 92 145 185
Preoperative sedation and analgesia†35 58 60 127 140 148 and as an adjunct to surgical anesthesia†.24 49 58 60 62 71 121 135 142 149 192
Treatment of opiate dependence in an office-based outpatient setting (designated an orphan drug by FDA for this use); used alone and in fixed combination with naloxone.201 202
Buprenorphine alone is preferred for the initial (i.e., induction) phase of treatment, administered under the supervision of the prescribing physician in the office setting.202 203 Following induction, buprenorphine in fixed combination with naloxone is preferred for maintenance treatment when use includes unsupervised administration.202 Administration of buprenorphine without naloxone in an unsupervised setting should be limited to patients who cannot tolerate naloxone.202
To avoid precipitating withdrawal, give the first dose of buprenorphine when clear, objective signs of opiate withdrawal are evident.202 In individuals using heroin or other short-acting opiates, administer the first dose ≥4 hours after the last use of the opiate; however, it is preferable to initiate buprenorphine when early signs of opiate withdrawal appear.202
Withdrawal symptoms can occur during buprenorphine induction in patients being transferred from methadone maintenance; withdrawal symptoms appear to be more likely in those receiving higher methadone dosages (>30 mg daily) and when the first dose of buprenorphine is given shortly after the last methadone dose.202
Administer by IM or IV injection for relief of pain.1 2 3 Administer sublingually as a single agent or in fixed combination with naloxone for management of opiate dependence.202
Also administered by continuous IV infusion†,32 33 34 by IM103 or IV76 79 injection using a patient-controlled infusion device†, and by epidural injection† for pain relief.23 24 25 26 28 29 30 31 50 78 92 192
For drug compatibility information, see Compatibility under Stability.
Administer as a single daily dose.202
Place tablets under the tongue and allow to dissolve; swallowing the tablets reduces bioavailability.202 Drinking warm fluids prior to administration may aid dissolution.204
For doses requiring >2 tablets, all the tablets may be placed under the tongue at once.202 Alternatively, patients may place 2 tablets under the tongue at a time if they are unable to place >2 tablets comfortably.202
To ensure consistent bioavailability, patients should adhere to the same manner of dosing with continued use.202
Administer over ≥2 minutes.1 2 3
Dilute to a concentration of 15 mcg/mL in 0.9% sodium chloride.32
Administer via a controlled-infusion device.32
Has been diluted to a concentration of 6–30 mcg/mL in 0.9% sodium chloride.23 24 25 26 28 29 30 31 78 92 192
The Drug Addiction Treatment Act (DATA) of 2000 allows qualifying physicians to prescribe and dispense opiates in schedules III, IV, and V of the Federal Controlled Substances Act that have been approved by FDA for detoxification or maintenance treatment of opiate dependence.205 Prior to passage of this law, opiate dependence treatment could be provided only at specially registered clinics.203 Under DATA 2000, prescription use of buprenorphine and buprenorphine/naloxone fixed combination in the treatment of opiate dependence is limited to physicians who meet certain requirements and have notified the Secretary of the US Department of Health and Human Services of their intent to prescribe these preparations for this indication.202
Pharmacists may contact 866-287-2728 or info@buprenorphine.samhsa.gov to verify whether a physician is in compliance with the provisions of DATA.203
Available as buprenorphine hydrochloride (injection and sublingual tablets); dosage expressed in terms of buprenorphine.1 2
Also available as fixed combination of buprenorphine hydrochloride and naloxone hydrochloride (sublingual tablets); dosage generally expressed in terms of the buprenorphine content.202
Adjust dosage according to the severity of pain, physical status of the patient, and other drugs that the patient is receiving.1 2
Children 2–12 years of age: 2–6 mcg/kg every 4–6 hours; however, longer dosing intervals (e.g., every 6–8 hours) may be sufficient.1 Do not use a fixed around-the-clock dosing interval until an adequate dosing interval has been established by clinical observation of the patient.1
Children ≥13 years of age: 0.3 mg given at intervals of up to every 6 hours as necessary.1 2 3 Repeat initial dose (up to 0.3 mg) once in 30–60 minutes, if needed.1
Exercise particular caution with IV administration, especially with initial doses.1
Decrease dosage by 50% in patients who are at increased risk of respiratory depression.1 (See Respiratory Effects under Cautions.)
Children 9 months to 9 years of age† undergoing circumcision: Initial dosage of 3 mcg/kg as an adjunct to surgical anesthesia, followed by additional 3-mcg/kg doses as necessary to provide analgesia postoperatively, has been used.27
Adjust dosage according to the severity of pain, physical status of the patient, and other drugs that the patient is receiving.1 2
0.3 mg given at intervals of up to every 6 hours as necessary.1 2 3 Repeat initial dose (up to 0.3 mg) once in 30–60 minutes, if needed.1 A dosing interval longer than 6 hours may be adequate in some patients.71 72 97 99
It may be necessary to administer single doses of up to 0.6 mg, but the manufacturer recommends that such relatively high doses only be administered IM and only to adults who are not at increased risk of respiratory depression.1
A regimen including an initial dose of 0.3 mg followed by another 0.3-mg dose repeated in 3 hours is as effective as a single 0.6-mg dose in relieving postoperative pain.129
Exercise particular caution with IV administration, especially with initial doses.1
Decrease dosage by 50% in patients who are at increased risk of respiratory depression.1 (See Respiratory Effects under Cautions.)
Dosages of 25–250 mcg/hour have been used for the management of postoperative pain.33 34
Dosages of 0.15–0.3 mg have been administered in the management of severe, chronic pain (e.g., in terminally ill patients) as frequently as every 6 hours, up to a mean total daily dosage of 0.86 mg (range: 0.15–7.2 mg).31
60 mcg as a single dose, up to a mean total dose of 180 mcg administered over a 48-hour period, has been used for the management of postoperative pain.23
Dosage of 0.3 mg has been used as a supplement to surgical anesthesia with a local anesthetic.24 192
Initially, buprenorphine 8 mg on day 1 and 16 mg on day 2.202 From day 3 onward, administer buprenorphine in fixed combination with naloxone at the same buprenorphine dose as on day 2.202
To avoid precipitating withdrawal, give the first dose when objective and clear signs of opiate withdrawal are evident.202
Manufacturer recommends that an adequate maintenance dosage, titrated to clinical effectiveness, be achieved as rapidly as possible to prevent undue opiate withdrawal symptoms.202
Target dosage of buprenorphine in fixed combination with naloxone is 16 mg daily; however, dosages as low as 12 mg daily may be effective in some patients.202 Adjust dosage in increments/decrements of 2 or 4 mg daily to a dosage that suppresses opiate withdrawal symptoms and ensures that the patient continues treatment.202
Usual dosage: 4–24 mg daily depending on the individual patient.202
The decision to discontinue therapy after a period of maintenance or brief stabilization should be made as part of a comprehensive treatment plan.202 Both gradual and abrupt discontinuance have been used; the best method for tapering dosage at the end of treatment has not been established.202
Children 2–12 years of age: Manufacturer states that there is insufficient evidence to recommend doses >6 mcg/kg or administration of a repeat dose within 30–60 minutes of the initial dose.1
There are insufficient clinical data to recommend single doses >0.6 mg for long-term use.1 2
Known hypersensitivity to buprenorphine or any ingredient in the formulation;1 2 buprenorphine/naloxone fixed combination is contraindicated in patients with known hypersensitivity to either component.202
Possible respiratory depression,1 2 4 18 28 33 39 44 48 58 59 62 64 71 73 75 76 84 89 93 95 97 184 185 especially with IV administration.202 Deaths have occurred when buprenorphine (usually in conjunction with a benzodiazepine) was misused via IV injection by opiate abusers.202 Deaths also have occurred when used with other depressants (e.g., alcohol, other opiates).202
Administer with caution and in reduced dosages in patients with pulmonary impairment or compromised respiratory function (e.g., those with COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression) or in those receiving other respiratory depressant drugs concomitantly.1 2 3 4 202
Naloxone1 2 3 4 9 21 40 64 71 84 and doxapram1 2 3 9 18 21 59 70 71 76 84 185 may be only partially effective in reversing buprenorphine-induced respiratory depression; use of assisted or controlled respiration may be necessary and should be considered the principal method of management.1 2 3 4 20 46 83
Use with caution in comatose patients or in patients with CNS depression.1
Performance of activities requiring mental alertness and physical coordination may be impaired.1 202
Concurrent use of other CNS depressants may potentiate CNS depression.1 202 (See Specific Drugs under Interactions.)
Cytolytic hepatitis and hepatitis with jaundice reported in individuals receiving buprenorphine for opiate dependence.202
Other serious adverse hepatic events (e.g., hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic encephalopathy) reported.202 Some individuals had risk factors for such adverse events (i.e., preexisting hepatic enzyme abnormalities, infection with hepatitis B or C virus, concomitant use of potentially hepatotoxic drugs, ongoing illicit use of injectable drugs), but the possibility exists that buprenorphine had a causative or contributory role.202
Evaluate liver function prior to initiation of buprenorphine for the management of opiate dependence and periodically during treatment.202 Evaluate carefully in the event of an adverse hepatic event.202
Sublingual administration of buprenorphine/naloxone fixed combination may cause withdrawal symptoms in individuals who are physically dependent on opiates if the fixed combination is administered before the agonist effects of the opiate have subsided.202
Marked and intense opiate withdrawal symptoms are likely if buprenorphine/naloxone fixed combination is misused via parenteral injection by individuals who are physically dependent on opiates.202
Buprenorphine may occasionally precipitate mild to moderate signs and symptoms of withdrawal in some patients physically dependent on opiates (because of the drug’s antagonist activity).1 2 87 100 112 183 202 Signs and symptoms of mild withdrawal may also appear following discontinuance of prolonged therapy with buprenorphine alone.4 71 84 100 112
Potential for elevation of CSF pressure as a result of vasodilation following carbon dioxide retention.1 Opiate effects may obscure the existence, extent, or course of intracranial pathology.1 Use with caution in patients with head injury, other intracranial lesions, or preexisting elevation in intracranial pressure.1
Acute and chronic hypersensitivity reactions reported.202 Rash,202 urticaria,202 and pruritus202 are most common;202 bronchospasm,202 angioedema,202 and anaphylactic shock202 also have occurred.202
Use with caution in debilitated patients and in those with hypothyroidism, Addison’s disease, toxic psychoses, prostatic hypertrophy or urethral stricture, acute alcoholism, delirium tremens, or kyphoscoliosis.1 202
Use with caution in patients with dysfunction of the biliary tract1 2 202 or those undergoing biliary tract surgery,54 since the drug may increase pressure within the common bile duct.1 2 21 40 52 54 202
May obscure the diagnosis and/or clinical course of patients with acute abdominal conditions.202
Possible orthostatic hypotension in patients who are ambulatory.202
Possible psychologic dependence to buprenorphine’s opiate agonist activity.1 12 112 Limited physical dependence may occur41 85 86 107 108 109 111 112 147 infrequently;1 2 4 74 178 tolerance to the drug’s opiate agonist activity develops rarely,107 109 171 178 if at all.84 96 123
When buprenorphine is used in fixed combination with naloxone, consider the cautions, precautions, and contraindications associated with naloxone.202
Category C.1 202
Safety and efficacy during labor and delivery not established.1 2
Distributed into milk.1 202 Women should not breast-feed infants while receiving buprenorphine.1 202
Safety and efficacy of parenteral buprenorphine as an analgesic not established in children <2 years of age.1 2 Has been used parenterally as a supplement to surgical anesthesia†27 and as an analgesic in the management of postoperative pain1 27 and severe chronic pain (e.g., in terminally ill patients)94 in a limited number of children 9 months to 18 years of age.1 27 94
Safety and efficacy of buprenorphine and buprenorphine/naloxone fixed combination not established for the management of opiate dependence in children <16 years of age.202
Use with caution.1 202
Metabolized in the liver; therefore, activity of the drug may be increased and/or prolonged in patients with hepatic impairment.1 2 Use with caution in patients with severe hepatic impairment.1 2 202
When used for the treatment of opiate dependence in patients with hepatic impairment, adjust dosage and observe the patient for potential withdrawal symptoms.202
Use with caution in patients with severe renal impairment.1 2 202
Sedation (e.g., drowsiness),1 2 3 9 40 44 48 51 53 65 67 69 71 72 75 79 83 95 96 98 110 183 184 185 dizziness,1 2 3 4 9 44 71 99 183 185 vertigo,1 2 3 nausea.1 2 3 4 40 44 49 51 53 67 71 76 79 83 93 105 183 184 185 192
Metabolized principally by CYP3A4.1 202
CYP3A4 inhibitors: Potential pharmacokinetic interaction (increased plasma buprenorphine concentrations).1 202 Closely monitor buprenorphine or buprenorphine/naloxone dosage; adjust dosage if necessary.1 202
CYP3A4 inducers: Potential pharmacokinetic interaction (decreased plasma buprenorphine concentrations).1 202 Closely monitor patient.1 202
Drugs that reduce hepatic blood flow may decrease the rate of hepatic elimination of buprenorphine.1 2 4 116
Drug | Interaction | Comments |
---|---|---|
Anesthetics, local (e.g., bupivacaine, mepivacaine) | Possible potentiation of anesthetic effect24 92 and more rapid onset and prolonged duration of analgesia24 | |
Anticoagulants, (phenprocoumon, no longer commercially available) | Possible purpuric response1 2 | |
Anticonvulsants (carbamazepine, phenobarbital, phenytoin) | Possible decrease in plasma buprenorphine concentrations1 202 | Monitor closely; adjust dosage of buprenorphine or buprenorphine/naloxone, if necessary1 202 |
Antifungals, azoles (e.g., ketoconazole) | Increased plasma buprenorphine concentrations1 202 | Monitor closely; adjust dosage of buprenorphine or buprenorphine/naloxone, if necessary1 202 |
Benzodiazepines (e.g., diazepam, lorazepam) | Reports of death or coma when buprenorphine was misused (e.g., self-injection of crushed tablets) via IV injection with benzodiazepines by drug abusers202 Respiratory and cardiovascular collapse reported in several patients receiving usual doses of IV buprenorphine and oral diazepam concomitantly1 2 59 Bradycardia, respiratory depression, and prolonged drowsiness reported following IV buprenorphine administration during surgery in a patient who had received oral lorazepam preoperatively36 | Use buprenorphine or buprenorphine/naloxone with caution in patients receiving benzodiazepines or other drugs with CNS effects202 |
CNS depressants (e.g., opiate agonists, tranquilizers, general anesthetics, sedatives/hypnotics, alcohol) | Possible potentiation of CNS depression1 2 3 35 37 42 59 60 64 | Use with caution; reduce dosage of at least one of the drugs1 2 3 202 |
Droperidol | Concomitant administration has produced satisfactory analgesia (during and after surgery60 and also in a terminally ill patient with severe, chronic pain that was previously unresponsive to buprenorphine alone37 ) | |
Fentanyl | Concomitant administration produced satisfactory analgesia of prolonged duration with minimal respiratory depression; patient was aroused quickly and easily following surgery70 | |
Halothane | Potential for increased and/or prolonged activity of buprenorphine secondary to reduced hepatic elimination of the drug1 2 4 116 186 191 | Use with caution; reduce dosage of at least one of the drugs1 186 189 |
HIV protease inhibitors (indinavir, ritonavir, saquinavir) | Increased plasma buprenorphine concentrations1 202 | Monitor closely; adjust dosage of buprenorphine or buprenorphine/naloxone, if necessary1 202 |
Macrolide antibiotics (e.g., erythromycin) | Increased plasma buprenorphine concentrations1 202 | Monitor closely; adjust dosage of buprenorphine or buprenorphine/naloxone, if necessary1 202 |
MAO inhibitors | Possible additive effect or potentiation of CNS depression1 2 3 | Use with caution1 2 3 |
Naloxone | In patients who received a single, high dose of buprenorphine before undergoing cholecystectomy with balanced anesthesia and experienced pain in the immediate postoperative phase, addition of naloxone resulted in adequate analgesia, possibly by counteracting dominant antagonistic effects of buprenorphine58 148 | |
Rifampin | Possible decrease in plasma buprenorphine concentrations1 202 | Monitor closely; adjust dosage of buprenorphine or buprenorphine/naloxone, if necessary1 202 |
Rapidly and approximately 40–90% absorbed following IM administration.116 118 Approximately 55% (range: 15–95%) absorbed following sublingual administration.118 119 Following oral administration, buprenorphine undergoes extensive first-pass metabolism in the GI mucosa and liver.122 131
Following IV administration of a single dose, mean peak plasma drug concentrations4 116 occurred within 2 minutes.4 116 118 Following IM administration of a second dose 3 hours after the initial IV dose, mean peak plasma concentrations occurred within 2–5 minutes.4 9 116 118
Approximately 10 minutes after administration, plasma buprenorphine concentrations are similar following IV or IM injection.4 9 116 118
Following parenteral administration of single doses in postoperative patients,1 2 3 9 16 21 42 48 71 72 80 82 96 97 98 121 123 124 127 128 the onset of analgesia usually occurs within 10–30 minutes.1 2 3 9 16 17 96 123 124 128 185 Peak analgesia usually occurs within 60 minutes1 71 80 96 128 185 but may occur within 15 minutes in some patients.71
Analgesia generally persists for 6 hours following single IM or IV doses,1 2 3 16 21 71 72 82 96 121 124 185 but has persisted for 4–10 hours following single IM doses1 2 3 16 21 71 72 82 96 97 98 123 124 127 184 and 2–24 hours following single IV doses.42 48 71 80 121 152
Rapidly (within several minutes) distributes into CSF following IV administration;3 63 117 120 CSF concentrations appear to be approximately 15–25% of concurrent plasma concentrations.117
Crosses the placenta in rats;71 not known whether buprenorphine crosses the placenta in humans.3
Distributes into human milk.1 2 3 4
Approximately 96%4 15 71 (mainly α- and β-globulins;4 71 does not appear to bind substantially to albumin).4
Almost completely metabolized in the liver,1 2 3 21 116 principally by N-dealkylation (mediated by CYP3A4)202 to form norbuprenorphine.3 4 71 113 114 115 118 122 125 202 Buprenorphine and norbuprenorphine undergo conjugation with glucuronic acid.3 71 118 122 125
Eliminated principally in feces3 4 113 (via biliary excretion4 113 ) and also in urine114 122 170 as unchanged drug and metabolites.
Biphasic or triphasic;114 116 118 half-life of terminal elimination phase is approximately 2.2 hours (range: 1.2–7.2 hours) following IV administration,1 2 4 21 40 118 119 and mean elimination half-life from plasma is 37 hours following sublingual administration.202
25°C (may be exposed to 15–30°C).202
<40°C; protect from prolonged exposure to light.1
For information on systemic interactions resulting from concomitant use, see Interactions.
Compatible |
---|
Bupivacaine HCl |
Glycopyrrolate with haloperidol lactate |
Incompatible |
Fludecate may be available in the countries listed below.
Fluphenazine decanoate (a derivative of Fluphenazine) is reported as an ingredient of Fludecate in the following countries:
International Drug Name Search
Esclebin may be available in the countries listed below.
Norfloxacin is reported as an ingredient of Esclebin in the following countries:
International Drug Name Search
Rec.INN
0030578-37-1
C12-H15-N3-O5-S
313
Sympathomimetic agent
Antihypotensive agent
Pyridazinium, 4-amino-6-methoxy-1-phenyl-, methyl sulfate
International Drug Name Search
Glossary
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Dofixim may be available in the countries listed below.
Cefpodoxime proxetil (a derivative of Cefpodoxime) is reported as an ingredient of Dofixim in the following countries:
International Drug Name Search
Flunarizine ratiopharm may be available in the countries listed below.
Flunarizine dihydrochloride (a derivative of Flunarizine) is reported as an ingredient of Flunarizine ratiopharm in the following countries:
International Drug Name Search
Morfin Epidural Meda may be available in the countries listed below.
Morphine hydrochloride (a derivative of Morphine) is reported as an ingredient of Morfin Epidural Meda in the following countries:
International Drug Name Search
AZ-250 may be available in the countries listed below.
Azithromycin dihydrate (a derivative of Azithromycin) is reported as an ingredient of AZ-250 in the following countries:
International Drug Name Search
Etoposide Aeon may be available in the countries listed below.
Etoposide is reported as an ingredient of Etoposide Aeon in the following countries:
International Drug Name Search
Factive is a brand name of gemifloxacin, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Factive available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Factive. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Imipem may be available in the countries listed below.
Cilastatin sodium salt (a derivative of Cilastatin) is reported as an ingredient of Imipem in the following countries:
Imipenem monohydrate (a derivative of Imipenem) is reported as an ingredient of Imipem in the following countries:
International Drug Name Search
Floksid may be available in the countries listed below.
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Floksid in the following countries:
International Drug Name Search
Treating severe, possibly life-threatening digoxin or digitoxin overdose.
Digoxin Immune Fab is an antidote for digoxin toxicity. It works by binding to digoxin and preventing it from working in the body.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Digoxin Immune Fab. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Digoxin Immune Fab. However, no specific interactions with Digoxin Immune Fab are known at this time.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Digoxin Immune Fab may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Digoxin Immune Fab as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Digoxin Immune Fab.
All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Digoxin Immune Fab. Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); fast or irregular heartbeat; fever.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Digoxin Immune Fab side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Digoxin Immune Fab is usually handled and stored by a health care provider. If you are using Digoxin Immune Fab at home, store Digoxin Immune Fab as directed by your pharmacist or health care provider. Keep Digoxin Immune Fab out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Digoxin Immune Fab. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Streptomycin Pharmadrug may be available in the countries listed below.
Streptomycin is reported as an ingredient of Streptomycin Pharmadrug in the following countries:
International Drug Name Search
Erythrotrop may be available in the countries listed below.
Erythromycin estolate (a derivative of Erythromycin) is reported as an ingredient of Erythrotrop in the following countries:
International Drug Name Search
Larylin Husten-Löser may be available in the countries listed below.
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Larylin Husten-Löser in the following countries:
International Drug Name Search
Cefotron may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Cefoperazone is reported as an ingredient of Cefotron in the following countries:
International Drug Name Search
Exuna may be available in the countries listed below.
Algestone Acetophenide is reported as an ingredient of Exuna in the following countries:
Estradiol 17ß-enantate (a derivative of Estradiol) is reported as an ingredient of Exuna in the following countries:
International Drug Name Search
Etoposide Injection may be available in the countries listed below.
Etoposide is reported as an ingredient of Etoposide Injection in the following countries:
International Drug Name Search
Prontinal may be available in the countries listed below.
Beclometasone 17α,21-dipropionate (a derivative of Beclometasone) is reported as an ingredient of Prontinal in the following countries:
International Drug Name Search
Vinblastin Richter may be available in the countries listed below.
Vinblastine is reported as an ingredient of Vinblastin Richter in the following countries:
Vinblastine sulfate (a derivative of Vinblastine) is reported as an ingredient of Vinblastin Richter in the following countries:
International Drug Name Search
Vetacaine may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Mepivacaine hydrochloride (a derivative of Mepivacaine) is reported as an ingredient of Vetacaine in the following countries:
International Drug Name Search
Clotrimazol HBF may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Clotrimazol HBF in the following countries:
International Drug Name Search
Etruzil may be available in the countries listed below.
Letrozole is reported as an ingredient of Etruzil in the following countries:
International Drug Name Search
In the US, Tofranil-PM (imipramine systemic) is a member of the drug class tricyclic antidepressants and is used to treat ADHD, Depression, Interstitial Cystitis, Night Terrors, Pain, Panic Disorder and Primary Nocturnal Enuresis.
US matches:
Imipramine embonate (a derivative of Imipramine) is reported as an ingredient of Tofranil-PM in the following countries:
International Drug Name Search
Escumycin may be available in the countries listed below.
Erythromycin is reported as an ingredient of Escumycin in the following countries:
International Drug Name Search
Dulcolax Lyfjaver may be available in the countries listed below.
Bisacodyl is reported as an ingredient of Dulcolax Lyfjaver in the following countries:
International Drug Name Search
Ecomesol may be available in the countries listed below.
Econazole nitrate (a derivative of Econazole) is reported as an ingredient of Ecomesol in the following countries:
International Drug Name Search
Migragesin may be available in the countries listed below.
Sumatriptan succinate (a derivative of Sumatriptan) is reported as an ingredient of Migragesin in the following countries:
International Drug Name Search
Turoptin may be available in the countries listed below.
Metipranolol is reported as an ingredient of Turoptin in the following countries:
International Drug Name Search
Losectil may be available in the countries listed below.
Omeprazole is reported as an ingredient of Losectil in the following countries:
International Drug Name Search
Téatrois may be available in the countries listed below.
Tiratricol is reported as an ingredient of Téatrois in the following countries:
International Drug Name Search
Axidronat may be available in the countries listed below.
Pamidronic Acid disodium salt (a derivative of Pamidronic Acid) is reported as an ingredient of Axidronat in the following countries:
International Drug Name Search